IVA — Inventiva S.A.
$3.71+3.06%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for IVA in the TickerWise workspace.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: FR
- Exchange: NASDAQ Global Market
- Employees: 114
- Website: https://www.inventivapharma.com
Latest SEC filings for IVA
Latest IVA news
- Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout Read article
- Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Here’s What Happened Read article
- Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Read article
- Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why Read article
- Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s What Happened Read article
- Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14 Read article
- Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Read article
- Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.